Pliant Therapeutics PLRX 深 沪
等待开盘 08-01 09:30:00 美东时间
1.465
-0.055
-3.62%
华盛通- 最 高1.57
- 今 开1.50
- 成交量 64.82万股
- 最 低 1.46
- 昨 收 1.52
- 总市值 8993.09万
- 52周最高 16.10
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 1.1001
- 委 比 57.66%
- 总股本 6138.63万
- 历史最高 43.92
- 量 比 0.91
- 振 幅 7.24%
- 历史最低 1.1001
- 每 手 1
- 风险率 5.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review
Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and operational changes align with next stepsSOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE
06-28 04:12
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following unfavorable safety and efficacy results from the BEACON-IPF Phase 2b/3 trial. While the drug showed modest improvements in lung function, it posed increased risks of disease progression and adverse events. The company is focusing on its oncology program, with PLN-101095 entering Phase 1 trials, and leveraging its proprieta...
06-27 20:05
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
06-13 03:08
Pliant Therapeutics Q1 EPS $(0.92) Misses $(0.74) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.74) by 24.32 percent. This is a 17.95 percent decrease over losses of $(0.78) per share
05-09 05:03
Pliant Therapeutics to trim about 45% of workforce
Pliant Therapeutics (NASDAQ:PLRX) said on Friday that it will cut approximately 45% of its current workforce, across all departments, amid the company's recent restructuring measures. The company will...
05-02 22:27
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Neutral.
03-18 23:53
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.
03-18 01:39
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Op...
03-13 23:04
Pliant Therapeutics Adopts Stockholder Rights Agreement
Pliant Therapeutics ( ($PLRX) ) just unveiled an update. On March 12, 2025, Pli...
03-13 21:18
